[Suppression of experimental footpad inflammatory reaction by anti-fungal agent liranaftate in mice].
To evaluate the effect of the thiocarbamate antifungal agent liranaftate on inflammation and itchiness, footpad edema by phorbol 12-myristate 13-acetate (PMA) and the paw-licking accompanying by perceptual stimuli by compound 48/80 were examined. The effect of liranaftate application to mouse footpad on paw-licking time by compound 48/80 was observed. Topical administration of 4% liranaftate 1 hr before compound 48/80 did not suppress the paw-licking time, while pyrilamine, an anti-histamine agent, suppressed it significantly. As liranaftate was reported to suppress the ear inflammation induced by PMA, the effect of this agent on the footpad edema by PMA was examined. Liranaftate application significantly suppressed the increase in footpad swelling 24 hr after application of PMA, as true with ear inflammation. In this condition, we measured the paw-licking time by compound 48/80, but the suppression of time was not observed by the agent with or without the suppression of footpad inflammation. From these observations, we conclude that liranaftate treatment suppresses late phase inflammatory reaction in feet, perhaps accompanied by cytokine production, though it may not relieve acute stimuli and itchiness through an anti-histamine effect directly.
Teikyo University Institute of Medical Mycology.
Naho
N
Maruyama
Sanae
S
Ishijima
Shigeru
S
Abe
D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D001522:Behavior, Animal / Q000187:drug effects*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D005534:Foot Diseases / Q000139:chemically induced / Q000188:drug therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D009281:Naphthalenes / Q000008:administration & dosage*; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D011725:Pyridines / Q000008:administration & dosage*; D013755:Tetradecanoylphorbol Acetate; D013859:Thiocarbamates / Q000008:administration & dosage*; D003189:p-Methoxy-N-methylphenethylamine
D000935:Antifungal Agents; D016207:Cytokines; D009281:Naphthalenes; D011725:Pyridines; D013859:Thiocarbamates; D003189:p-Methoxy-N-methylphenethylamine; C470235:liranaftate; D013755:Tetradecanoylphorbol Acetate